Literature DB >> 20524087

Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.

Manal M Zyada1.   

Abstract

This study was designed to determine the potential role of survivin in the pathogenesis of Burkitt´s lymphoma (BL) and analyzing the relationship of its expression with response to therapy. The expression of survivin was investigated in seven archival tumor tissues of BL using the streptavidin-biotin complex technique. Immunohistochemical analysis showed that survivin expression was positive in 6 of 7 BL cases (85.7%). BL group with high survivin expression had poor response to chemotherapy than the group with low survivin expression (P=0.005). The results suggest that apoptosis inhibition by survivin is a significant prognostic parameter of poor response to chemotherapy in Burkitt's lymphoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524087     DOI: 10.1007/s12032-010-9581-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin.

Authors:  Jose A Rodríguez; Simone W Span; Carlos G M Ferreira; Frank A E Kruyt; Giuseppe Giaccone
Journal:  Exp Cell Res       Date:  2002-04-15       Impact factor: 3.905

Review 2.  Survivin: role in diagnosis, prognosis, and treatment of bladder cancer.

Authors:  Mohammed Akhtar; Lisa Gallagher; Stephen Rohan
Journal:  Adv Anat Pathol       Date:  2006-05       Impact factor: 3.875

Review 3.  Survivin as a target for new anticancer interventions.

Authors:  Nadia Zaffaroni; Marzia Pennati; Maria Grazia Daidone
Journal:  J Cell Mol Med       Date:  2005 Apr-Jun       Impact factor: 5.310

4.  Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians.

Authors:  Tham Chee Kian; Tao Miriam; Quek Richard; Yap Swee Peng; Loong Er Li; Sng Ivy; Tan Leonard Hwan-Cheong; Li Hui Hua; Lim Soon Thye
Journal:  Leuk Lymphoma       Date:  2008-04

Review 5.  [Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance].

Authors:  Frédérique Vegran; Romain Boidot; Claire Oudin; Jean-Marc Riedinger; Sarah Lizard-Nacol
Journal:  Bull Cancer       Date:  2005-03       Impact factor: 1.276

Review 6.  [Role of survivin in mitosis].

Authors:  Kamila Wolanin; Katarzyna Piwocka
Journal:  Postepy Biochem       Date:  2007

7.  Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients.

Authors:  E Okada; Y Murai; K Matsui; S Isizawa; C Cheng; M Masuda; Y Takano
Journal:  Cancer Lett       Date:  2001-02-10       Impact factor: 8.679

Review 8.  Survivin: a promising biomarker for detection and prognosis of bladder cancer.

Authors:  Vitaly Margulis; Yair Lotan; Shahrokh F Shariat
Journal:  World J Urol       Date:  2007-10-26       Impact factor: 4.226

9.  Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection.

Authors:  Seiko Iwata; Kaoru Wada; Satomi Tobita; Kensei Gotoh; Yoshinori Ito; Ayako Demachi-Okamura; Norio Shimizu; Yukihiro Nishiyama; Hiroshi Kimura
Journal:  J Gen Virol       Date:  2009-09-30       Impact factor: 3.891

Review 10.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer.

Authors:  E C LaCasse; S Baird; R G Korneluk; A E MacKenzie
Journal:  Oncogene       Date:  1998-12-24       Impact factor: 9.867

View more
  2 in total

1.  Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma.

Authors:  Douglas H Thamm; Jenette K Joseph; Barbara J Rose; Travis K Meuten; Kristen M Weishaar
Journal:  BMC Vet Res       Date:  2020-03-24       Impact factor: 2.741

2.  Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K⁺ channels.

Authors:  Shuai Zhang; Bo Liu; Zaiwen Fan; Dong Wang; Ying Liu; Jian Li; Ning Wang; Yi Liu; Bo Zhang
Journal:  Mol Med Rep       Date:  2016-03-04       Impact factor: 3.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.